All In Biotech

Drug Trial Radar · NCT03987763

A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis

A Phase 4, Open-Label, Multicenter Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-122 Lotion in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Oct 22, 2019

Primary completion

Nov 2026

Study completion Apr 2027

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Jun 17, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the safety, the systemic exposure of halobetasol propionate (HP), and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-122 lotion in pediatric participants with moderate to severe plaque psoriasis.

Conditions

  • Psoriasis

Interventions

  • IDP-122 LotionDrug

    Topical

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics: Maximum Observed Drug (Halobetasol Propionate) Concentration in Plasma (Cmax) of IDP-122 Lotion AnalytesTime frame: 0 (predose), 1, 2, 4, 8, 12, and 24 hours postdose

Locations

9 sites in 3 countries. Site status is shown where the registry gives one.

  • Bausch Site 11

    Fountain Valley, California

  • Bausch Site 2

    Thousand Oaks, California

  • Bausch Site 07

    Doral, Florida

  • Bausch Site 3

    Miami, Florida

  • Bausch Site 06

    Miami, Florida

  • Bausch Site 05

    Spartanburg, South Carolina

  • Bausch Site 1

    Spokane, Washington

  • Bausch Site 12

    Santo Domingo, Dominican Republic

  • Bausch Site 4

    Panama City, Panama

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.